Cargando…

Bispecific protein targets prostate cancer

Detalles Bibliográficos
Autor principal:	Burgess, Antony W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	News
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482589/ https://www.ncbi.nlm.nih.gov/pubmed/28455964 http://dx.doi.org/10.18632/oncotarget.17372

Ejemplares similares

A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand
por: Lee, Sung Chang, et al.
Publicado: (2021)

TCAF1 puts a chill on prostate cancer
por: Leslie, Mitch
Publicado: (2015)

Can THEM6 targeting stop resistance to prostate cancer treatment?
por: Chattopadhyay, Mrittika, et al.
Publicado: (2022)

Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
por: Heitmann, Jonas S., et al.
Publicado: (2021)

Co‐targeting driver pathways in prostate cancer: two birds with one stone
por: Zoubeidi, Amina, et al.
Publicado: (2018)

Regulating the prostate
por: Tuma, Rabiya S.
Publicado: (2005)

Organochlorines and Prostate Cancer in Japan: No Link in Men without Occupational Exposures
por: Freeman, Kris S.
Publicado: (2010)

FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?
por: Gallo, Leandro H.
Publicado: (2021)

Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
por: Simão, Diana C., et al.
Publicado: (2023)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Selective inhibitors of nuclear export: potential therapeutics for AR variant-expressing prostate cancer
por: Antonarakis, Emmanuel S.
Publicado: (2018)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy
por: Zhang, Tiancheng, et al.
Publicado: (2023)

PSMA brings new flavors to PI3K signaling: A role for glutamate in prostate cancer
por: Palamiuc, Lavinia, et al.
Publicado: (2018)

Synthesis and Preclinical Evaluation of Three Novel (68)Ga-Labeled Bispecific PSMA/FAP-Targeting Tracers for Prostate Cancer Imaging
por: Verena, Arsyangela, et al.
Publicado: (2023)

CDK8: a new breast cancer target
por: Crown, John
Publicado: (2017)

A target of potential RELAvance in inflammatory breast cancer
por: Eckhardt, Bedrich L., et al.
Publicado: (2017)

Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
por: Sun, Yanze, et al.
Publicado: (2023)

A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells
por: Lund, Maria E., et al.
Publicado: (2020)

Acute myeloid leukemia targets for bispecific antibodies
por: Hoseini, S S, et al.
Publicado: (2017)

Acute myeloid leukemia targets for bispecific antibodies
por: Hoseini, S S, et al.
Publicado: (2017)

Nanocell targeting using engineered bispecific antibodies
por: Taylor, Karin, et al.
Publicado: (2014)

Why isn’t the angiotensin type 1 receptor a target in cancer?
por: Vinson, Gavin P.
Publicado: (2017)

Self-targeting blocks malaria parasite invasion
por: Deitsch, Kirk W.
Publicado: (2015)

Targeting the Tumor Microenvironment with Fluorescence-Activatable Bispecific Endoglin/Fibroblast Activation Protein Targeting Liposomes
por: Tansi, Felista L., et al.
Publicado: (2020)

In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer
por: Thakur, Archana, et al.
Publicado: (2015)

Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy
por: Huang, Shuyu, et al.
Publicado: (2020)

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
por: Freedman, Joshua D, et al.
Publicado: (2017)

Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway()
por: Dickinson, Louise, et al.
Publicado: (2013)

Quantification of cell surface proteins with bispecific antibodies
por: Panke, C., et al.
Publicado: (2013)

A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer
por: Nucera, Carmelo
Publicado: (2019)

From discovery of tyrosine phosphorylation to targeted cancer therapies: The 2018 Tang Prize in Biopharmaceutical Science
por: Yu, Jau-Song
Publicado: (2019)

VHH-Based Bispecific Antibodies Targeting Cytokine Production
por: Nosenko, Maxim A., et al.
Publicado: (2017)

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells
por: Bühler, P., et al.
Publicado: (2007)

Cancer immunomodulation using bispecific aptamers
por: Thomas, Brian J., et al.
Publicado: (2022)

Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
por: Blanco, Belén, et al.
Publicado: (2021)

Targeting the inner nuclear membrane
por: Tuma, Rabiya
Publicado: (2004)

RNA targeting gets competitive
por: Short, Ben
Publicado: (2011)

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
por: Rabia, Emilia, et al.
Publicado: (2023)

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
por: Farhangnia, Pooya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4mjmh78enij4i4gk5q2iplp0qs